Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows [...]
0
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Tuesday, November [...]
Study on Abnormal MRIs and the Risk of Developing MS Featured in the International Journal of MS Care (Hackensack, NJ, October [...]
Optimizing Multiple Sclerosis Management: New CME/CE Regional Courses for Healthcare Professionals (Hackensack, NJ, October 2014)— The [...]
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Once-daily Aubagio is the only oral treatment to [...]
Employment in Multiple Sclerosis (MS) Study Multiple sclerosis (MS), the leading cause of neurological disability among young and [...]
Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™ [...]
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In [...]
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS [...]
International Journal of MS Care Features Article on the Multiple Sclerosis Self-Management Scale (Hackensack, NJ, August 2014)—The [...]
